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A Meta-analysis of Clinical Advancement in 
Sanfilippo Syndrome Type A
Kassidi Petersen, Molly Ross, Molly Felix, Lauren Grillo, Cassandra Marshall, Dr. Julia Oxford
INTRODUCTION
Background information about the disease
Sanfilippo syndrome (also known as MPSIII) type A is caused by the mutation of the gene 
encoding SGSH, N-sulfoglucosamine sulfohydrolase, on chromosome 17, region 17q25.3
● It is a recessive gene that affects around 1 in 70,000 babies each year
● This mutation affects the mucopolysaccharides and causes the patient to lose 
an enzyme that is crucial to breaking down heparan sulfate 
○ Heparan sulfate is stored in the cells instead of breaking down 
and causes progressive damage 
● Symptoms become apparent after the age of 1-years-old 
○ Learning abilities decline after the ages of 2 and 6
○ The symptoms and progression rate are different in each 
patient
○ Limit of physical growth, resulting in small stature 
○ Other common symptoms include:
■ Behavioral problems 
■ Coarse facial features 
■ Full lips
■ Heavy brows 
■ Sleep difficulties 
■ Stiff joints 
■ Difficulting walking 
● Diagnosis includes a urine test looking for high levels of mucopolysaccharides 
Child with MPS III syndrome. Image taken from National MPS society 
PROSPECTIVE TREATMENT
Enzyme Replacement Therapy and Outcomes
Enzyme replacement therapy has gone through multiple trials to see if testing different ways to replace the missing 
enzyme that inhibits the degradation of MPS.
● Animal models of enzyme therapy 
○ Protein fusion and direct administration to CNS have been proven effective 
○ Problems are a high concentration of enzymes are needed and fusion to CNS is 
highly invasive and may not work on children, the main affected population 
● Clinical enzyme replacement trials 
○ Began in 2016 with 12 patients 
○ In the trial recombinant human heparan-N-Sulfatase has been administered 
intrathecally to each of the patients monthly 
○ 4 showed a decline in development 6 remained stable and 2 were inconclusive 
Ex Vivo gene therapy applied to bone marrow tissue. 
Gene therapy in Sanfilippo Syndrome Type A is used in hopes that the stem cells that are introduced from the 
bone marrow of a healthy individual will be catalytically active and this activity will spread to native cells so that 
they will be catalytically active too.
● Preliminary testing in mice showed significant decrease in activity after treatment if treated early. 
Mice treated with a Sulfate Modifying Factor 1 in the SGSH gene using an internal ribosomal entry 
site (SGSH-IRES-SUMF1) showed activity similar to normal mice. Early treatment by injection 
was sufficient in prevention or delay of central nervous system issues in mice with Sanfilippo 
Syndrome. This study and others like it allowed human clinical trials to begin.  (Fraldi A, et al.)
● In human trials, a similar result was found. The best outcomes are from younger patients who 
received treatment early. During the trials, patients showed no negative side effects at the 
injection site. ( Tardieu M,et al.)
Treatment for this disease using stem cells in bone marrow is still in trials but looks hopeful.
Lidia Gaffke Summary of studies conducted on development of therapies for Sanfilippo disease 
(MPS III) and reported during last 3 years (2014–2017)
CONCLUSION
Overall, treatments for Sanfilippo Syndrome type A are still in the preliminary stages.  Enzyme 
replacement therapy and gene therapy currently are at the forefront of research.  The 
advancement of clinical trials to human subjects will be of principal interest as research continues. 
MPS III is a syndrome associated with high lethality: it is crucial that therapies are effective for 
young individuals.  Due to this, our meta-analysis found gene therapy to be a more promising 
avenue of treatment.  Future research should heavily invest in gene therapy to improve 
outcomes for affected individuals. 
Psychological and Cultural 
Considerations
Psychological Symptom Management:
Sanfilippo syndrome presents initially with psychosomatic symptoms, similar to those seen in 
individuals with ADHD.  Research into management of these symptoms is critical to patient 
wellbeing as well as elevating quality of life.  
Cultural Considerations:
Attention to areas of prevalence should also be taken into account with this syndrome.  
Geographic distribution of Sanfilippo shows the highest density of cases in Australia.  Distribution 
data outside of Europe and Australia is lacking. It is highly possible that cases are under reported 
in developing countries.  
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